Synlogic, Inc. (NASDAQ:SYBX – Get Free Report)’s stock price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.97 and traded as high as $1.22. Synlogic shares last traded at $1.22, with a volume of 501 shares trading hands.
Synlogic Price Performance
The stock has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $0.77. The company has a market cap of $14.33 million, a P/E ratio of -4.50 and a beta of 0.48.
Hedge Funds Weigh In On Synlogic
Large investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in shares of Synlogic in the 3rd quarter worth approximately $49,000. Renaissance Technologies LLC increased its stake in shares of Synlogic by 116.7% during the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 46,117 shares during the period. Finally, DRW Securities LLC bought a new stake in Synlogic during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 63.40% of the company’s stock.
About Synlogic
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
Further Reading
- Five stocks we like better than Synlogic
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
